Companies
Locus Biosciences
CDMO services — Scalable GMP manufacturing.
- Country
- United States
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | Total funding ranges from $136.23M to $165.4M | prospeo.io |
| Capacity | Millions of doses annually, up to 200 L scale per phage | locus-bio.com |
| Certification | 2021 ISPE Facility of the Year Award (Honorable Mention) | ipsdb.com · locus-bio.com |
| Regulatory approval | Compliant with US (FDA) and international standards (EMA, PMDA) | ipsdb.com · locus-bio.com |
| Production site | 12,000 sq. ft. cGMP facility in Morrisville, North Carolina | bekbg.com · ipsdb.com · locus-bio.com |
| Headcount | 55-61 employees as of 2026 medium confidence | prospeo.io |
| Revenue | Estimated annual revenue ranges from $3M to $15.9M medium confidence | prospeo.io |
Independent sources: bekbg.com · ipsdb.com · locus-bio.com · prospeo.io
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Bacteriophage therapy | therapeutics-platforms | High | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.